Research
Size:
Share:

PREFERMS – Sponsored by Novartis

Active Study

This 12-month, Prospective, Randomized, active-controlled, open-label study to evaluate patient retention of Fingolimod vs. approved first-line disease modifying therapies in adults with relapsing remitting Multiple Mclerosis (PREFERMS) Imaging Services (OCT) and Ophthalmic exams for two neurologists participating in this study being carried out in our Fairfax, Va. office.

Return to Other Studies